Verastem Inc
NASDAQ:VSTM
Intrinsic Value
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. [ Read More ]
The intrinsic value of one VSTM stock under the Base Case scenario is 9.43 USD. Compared to the current market price of 11.82 USD, Verastem Inc is Overvalued by 20%.
Valuation Backtest
Verastem Inc
Run backtest to discover the historical profit from buying and selling VSTM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Verastem Inc
Current Assets | 143.7m |
Cash & Short-Term Investments | 137.1m |
Other Current Assets | 6.6m |
Non-Current Assets | 6m |
PP&E | 1.2m |
Other Non-Current Assets | 4.8m |
Current Liabilities | 26.4m |
Accounts Payable | 7.2m |
Accrued Liabilities | 18.9m |
Other Current Liabilities | 327k |
Non-Current Liabilities | 44.8m |
Long-Term Debt | 40.1m |
Other Non-Current Liabilities | 4.7m |
Earnings Waterfall
Verastem Inc
Revenue
|
0
USD
|
Operating Expenses
|
-92.1m
USD
|
Operating Income
|
-92.1m
USD
|
Other Expenses
|
4.7m
USD
|
Net Income
|
-87.4m
USD
|
Free Cash Flow Analysis
Verastem Inc
What is Free Cash Flow?
VSTM Profitability Score
Profitability Due Diligence
Verastem Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Verastem Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
VSTM Solvency Score
Solvency Due Diligence
Verastem Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Verastem Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
VSTM Price Targets Summary
Verastem Inc
According to Wall Street analysts, the average 1-year price target for VSTM is 29.36 USD with a low forecast of 17.68 USD and a high forecast of 37.8 USD.
Ownership
VSTM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
VSTM Price
Verastem Inc
Average Annual Return | -18.45% |
Standard Deviation of Annual Returns | 64.1% |
Max Drawdown | -94% |
Market Capitalization | 298.8m USD |
Shares Outstanding | 25 268 100 |
Percentage of Shares Shorted | 3.04% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Needham, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one VSTM stock under the Base Case scenario is 9.43 USD.
Compared to the current market price of 11.82 USD, Verastem Inc is Overvalued by 20%.